



# Online Exhibit Portfolio

## Practical Pediatric Dermatology for Primary Care



Practical Pediatric Dermatology for Primary Care Live Webinar  
May 21, 2021  
8:00 am – 11:30 am CST

This activity is planned and hosted by the University of Minnesota Department of Dermatology

[med.umn.edu/dermatology](https://med.umn.edu/dermatology)

## **Acknowledgement of Support**

Practical Pediatric Dermatology for Primary Care received  
exhibit support from the following:

Molnlycke

Regeneron

Verrica


# The Simple Six

## FOR WOUND CARE STANDARDIZATION

Mepilex® Border Flex



Exufiber® Ag +



Mepilex® Border Sacrum



Mepilex® Border Heel



Mepilex® Transfer



Mepilex® Border Post-Op Ag



Join us in our 3-D Booth to Learn More  
or email Lindsey Sarrack at [Lindsey.sarrack@molnlycke.com](mailto:Lindsey.sarrack@molnlycke.com)



# See What's Possible With DUPIXENT

Visit our virtual booth  
experience today

**DUPIXENT**<sup>®</sup>  
(dupilumab)

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation around the globe.

Regeneron is a leading biotechnology company that invents medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments, almost all of which were homegrown in our laboratories.

Explore Our  
Virtual Booth  
Experience!



Click or Scan

Contact Us:

[Medical.information@regeneron.com](mailto:Medical.information@regeneron.com)

☎ 1-844-734-6643

SANOFI GENZYME 

**REGENERON**



Verrica Pharmaceuticals is very pleased to support the University of Minnesota's Practical Pediatric Dermatology for Primary Care program

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients. VP-102, our lead product candidate, is a drug-device combination topical therapy that has the potential to be the first product approved by the FDA to treat molluscum contagiosum (molluscum). If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name, YCANTH™. Results suggest that YCANTH™, if approved, could potentially improve both clinical practice and patient outcomes by providing molluscum patients with a new treatment option.

Verrica has also entered a worldwide license agreement with Lytix Biopharma AS ("Lytix") to develop and commercialize LTX-315 for dermatologic oncology conditions. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indication for development.

For more information click below:

[VISIT OUR VIRTUAL EXHIBIT](#)

For molluscum patient education click below:

[www.aboutmolluscum.com](http://www.aboutmolluscum.com)